ERBB2 and breast cancer: Few studies have focused on IILRR because advances in surgical technique, radiotherapy, and extensive use of adjuvant systemic therapies have reduced the rate of local recurrences in patients with HER2-negative luminal breast cancer than before [4, 8, 17].